Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-31 @ 2:41 PM
Study NCT ID:
NCT03071094
Status:
TERMINATED
Last Update Posted:
2021-11-19
First Post:
2017-02-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
Sponsor:
Transgene
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-07-27
Start Date Type:
ACTUAL
Primary Completion Date:
2020-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-02-03
Completion Date Type:
ACTUAL
First Submit Date:
2017-02-10
First Submit QC Date:
None
Study First Post Date:
2017-03-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-09-22
Results First Submit QC Date:
None
Results First Post Date:
2021-11-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-10-21
Last Update Post Date:
2021-11-19
Last Update Post Date Type:
ACTUAL